C 1821短期口服治疗对未经治疗的癌症患者的免疫调节作用：一项对照研究。

Immunomodulating effects of a short-term oral treatment with C 1821 in untreated cancer patients: a controlled study.

作者信息

Lang J M, Aleksijevic A, Giron C, Levy S, Falkenrodt A, Mayer S, Stoclet J C, Oberling F

出版信息

Adv Exp Med Biol. 1983;166:171-80. doi: 10.1007/978-1-4757-1410-4_14.

Abstract

C 1821 is a purified glycoprotein extract from Klebsiella pneumoniae serotype 2 with a molecular weight of about 350,000. It enhances immune responses in animals when given orally and the oral route of administration is devoided of any toxicity even in humans. The present controlled trial showed that C 1821 given per os at the single daily dose of 4 mg for 14 days in untreated cancer patients (mostly lymphomas) significantly enhanced delayed cutaneous hypersensitivity to recall antigens using the Multitest system (7 antigens). It also increased basal levels of lymphocyte cAMP and particularly of cGMP which were decreased in these patients. When incubated in vitro with lymphocytes from either normal controls or patients, C 1821 showed a dose-dependent stimulation of cAMP synthesis which was more pronounced in patients than in controls.

摘要

C 1821是一种从2型肺炎克雷伯菌中提取的纯化糖蛋白提取物，分子量约为350,000。口服给予动物时，它能增强免疫反应，即使对人类而言，口服给药途径也没有任何毒性。目前的对照试验表明，在未经治疗的癌症患者（主要是淋巴瘤患者）中，每天口服4毫克C 1821，持续14天，使用多重检测系统（7种抗原）显著增强了对回忆抗原的迟发型皮肤超敏反应。它还提高了淋巴细胞环磷酸腺苷（cAMP）的基础水平，尤其是环磷酸鸟苷（cGMP）的基础水平，而这些患者体内的cGMP水平原本是降低的。当与正常对照者或患者的淋巴细胞在体外一起孵育时，C 1821表现出对cAMP合成的剂量依赖性刺激，这种刺激在患者中比在对照者中更明显。